Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review
- PMID: 12185293
- DOI: 10.1634/theoncologist.7-4-288
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review
Abstract
Although 5-fluorouracil (5-FU) was first introduced in 1957, it remains an essential part of the treatment of a wide range of solid tumors. 5-FU has antitumor activity against epithelial malignancies arising in the gastrointestinal tract and breast as well as the head and neck, with single-agent response rates of only 10%-30%. Although 5-FU is still the most widely prescribed agent for the treatment of colorectal cancer, less than one-third of patients achieve objective responses. Recent research has focused on the biomodulation of 5-FU to improve the cytotoxicity and therapeutic effectiveness of this drug in the treatment of advanced disease. As all the anticancer agents, 5-FU leads to several toxicities. The toxicity profile of 5-FU is schedule dependent. Myelotoxicity is the major toxic effect in patients receiving bolus doses. Hand-foot syndrome (palmar-plantar erythrodysesthesia), stomatitis, and neuro- and cardiotoxicities are associated with continuous infusions. Other adverse effects associated with both bolus-dose and continuous-infusion regimens include nausea and vomiting, diarrhea, alopecia, and dermatitis. All these reasons explain the need for more effective and less toxic fluoropyrimidines. In the first part of this review, we briefly present the metabolic pathways of 5-FU responsible for the efficacy and toxicity of this drug. This knowledge is also necessary to understand the target(s) of biomodulation. The second part is devoted to a review of the literature on three recent prodrugs of 5-FU, i.e., capecitabine, UFT (ftorafur [FTO] plus uracil), and S-1 (FTO plus 5-chloro-2,4-dihydroxypyridine plus potassium oxonate). The pharmacological principles that have influenced the development of these new drugs and our current knowledge of the clinical pharmacology of these new agents, focusing on antitumor activity and toxicity, are presented. The literature was analyzed until March 2002. This review is intended to be as exhaustive as possible since it was conceived as a work tool for readers wanting to go further.
Similar articles
-
The prodrugs of 5-fluorouracil.Curr Med Chem Anticancer Agents. 2002 Mar;2(2):267-310. doi: 10.2174/1568011023354146. Curr Med Chem Anticancer Agents. 2002. PMID: 12678747 Review.
-
The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.Anticancer Drugs. 2004 Feb;15(2):85-106. doi: 10.1097/00001813-200402000-00001. Anticancer Drugs. 2004. PMID: 15075664 Review.
-
Practical considerations in the use of oral fluoropyrimidines.Semin Oncol. 2003 Jun;30(3 Suppl 6):88-92. doi: 10.1016/s0093-7754(03)00135-0. Semin Oncol. 2003. PMID: 12802799 Review.
-
Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.Nat Clin Pract Oncol. 2005 Nov;2(11):578-87. doi: 10.1038/ncponc0353. Nat Clin Pract Oncol. 2005. PMID: 16270098 Review.
-
Capecitabine: a review.Clin Ther. 2005 Jan;27(1):23-44. doi: 10.1016/j.clinthera.2005.01.005. Clin Ther. 2005. PMID: 15763604 Review.
Cited by
-
[Hand-foot syndrome with capecitabine therapy].Hautarzt. 2007 Jun;58(6):532-6. doi: 10.1007/s00105-006-1183-y. Hautarzt. 2007. PMID: 16897045 German.
-
Investigation of aromatase inhibitory activity of metal complexes of 8-hydroxyquinoline and uracil derivatives.Drug Des Devel Ther. 2014 Aug 14;8:1089-96. doi: 10.2147/DDDT.S67300. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25152615 Free PMC article.
-
The Prevalence of 5-Fluorouracil and Capecitabine Cardiotoxicity: A Systematic Review and Meta-Analysis.World J Oncol. 2024 Dec;15(6):902-921. doi: 10.14740/wjon1920. Epub 2024 Oct 30. World J Oncol. 2024. PMID: 39697430 Free PMC article.
-
Linking uracil base excision repair and 5-fluorouracil toxicity in yeast.Nucleic Acids Res. 2006 Jan 10;34(1):140-51. doi: 10.1093/nar/gkj430. Print 2006. Nucleic Acids Res. 2006. PMID: 16407331 Free PMC article.
-
Biosolvation Nature of Ionic Liquids: Molecular Dynamics Simulation of Methylated Nucleobases in Hydrated 1-Ethyl-3-methylimidazolium Acetate.ACS Omega. 2018 Jul 26;3(7):8344-8354. doi: 10.1021/acsomega.8b01231. eCollection 2018 Jul 31. ACS Omega. 2018. PMID: 31458966 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials